Migraine medical device has better patient compliance than oral medicine

Cefaly Technology, has released data that shows its migraine medical device, Cefaly, has better long-term patient compliance than preventative migraine medication

In March 2014, the FDA approved Cefaly the first prescription-only, headband-like, device which uses tiny electrical impulses to stimulate the trigeminal nerve to reduce the frequency and intensity of migraines.

Cefaly Technology collected data on 14,745 migraine patients who acquired the device between March 2014 and October 2015.

Knowing that the device is used with an electrode that has to be replaced every month, the company was able to assess the compliance of the treatment based on the recurrent orders of electrodes.

If all patients where using the device daily, in accordance to their doctor's recommendation, the compliance would be 100%, but the actual electrode consumption reveals that the compliance is 72.4%, which is twice the compliance rate usually reported for oral preventive migraine medication according to the company.

Pierre Rigaux, chief executive officer of Cefaly Technology, the maker of the device, said: "This is a great confirmation that the Cefaly is a better solution than medications for migraine prophylaxis.

"Not only does the high safety and the unlikely yet minor side effects explain the high compliance, the patient satisfaction for the efficacy does too.

“With the recent published clinical trials and the newest data from several clinical trials in the US, this compliance data demonstrates that Cefaly is becoming the first-line treatment for patients who suffer from frequent migraine."